FY2025 EPS Estimates for VNDA Raised by Cantor Fitzgerald

Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) – Stock analysts at Cantor Fitzgerald boosted their FY2025 EPS estimates for shares of Vanda Pharmaceuticals in a note issued to investors on Thursday, October 30th. Cantor Fitzgerald analyst O. Brayer now anticipates that the biopharmaceutical company will post earnings per share of ($1.87) for the year, up from their prior estimate of ($2.03). Cantor Fitzgerald currently has a “Overweight” rating and a $11.00 target price on the stock. The consensus estimate for Vanda Pharmaceuticals’ current full-year earnings is ($1.12) per share. Cantor Fitzgerald also issued estimates for Vanda Pharmaceuticals’ FY2026 earnings at ($2.42) EPS.

Vanda Pharmaceuticals (NASDAQ:VNDA) last released its quarterly earnings results on Wednesday, October 29th. The biopharmaceutical company reported ($0.38) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.31) by ($0.07). The business had revenue of $56.26 million for the quarter, compared to the consensus estimate of $58.73 million. Vanda Pharmaceuticals had a negative net margin of 39.70% and a negative return on equity of 16.44%. Vanda Pharmaceuticals has set its FY 2025 guidance at EPS.

VNDA has been the topic of several other research reports. Weiss Ratings reiterated a “sell (d-)” rating on shares of Vanda Pharmaceuticals in a report on Wednesday, October 8th. Wall Street Zen upgraded shares of Vanda Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Saturday. Finally, HC Wainwright reiterated a “buy” rating and issued a $20.00 target price on shares of Vanda Pharmaceuticals in a report on Thursday, August 21st. Two equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, Vanda Pharmaceuticals currently has an average rating of “Hold” and a consensus price target of $15.50.

Vanda Pharmaceuticals Trading Up 2.8%

Vanda Pharmaceuticals stock opened at $4.47 on Monday. The company has a market capitalization of $264.13 million, a P/E ratio of -3.15 and a beta of 0.74. The firm’s fifty day simple moving average is $4.94 and its 200-day simple moving average is $4.65. Vanda Pharmaceuticals has a 1-year low of $3.81 and a 1-year high of $5.70.

Hedge Funds Weigh In On Vanda Pharmaceuticals

A number of institutional investors have recently modified their holdings of the stock. Millennium Management LLC raised its stake in shares of Vanda Pharmaceuticals by 220.0% in the first quarter. Millennium Management LLC now owns 2,139,591 shares of the biopharmaceutical company’s stock worth $9,821,000 after acquiring an additional 1,470,898 shares during the last quarter. Geode Capital Management LLC raised its stake in shares of Vanda Pharmaceuticals by 4.8% in the second quarter. Geode Capital Management LLC now owns 1,691,638 shares of the biopharmaceutical company’s stock worth $7,986,000 after acquiring an additional 77,997 shares during the last quarter. Krensavage Asset Management LLC raised its stake in shares of Vanda Pharmaceuticals by 35.9% in the second quarter. Krensavage Asset Management LLC now owns 1,024,883 shares of the biopharmaceutical company’s stock worth $4,837,000 after acquiring an additional 270,502 shares during the last quarter. Connor Clark & Lunn Investment Management Ltd. raised its stake in shares of Vanda Pharmaceuticals by 13.5% in the first quarter. Connor Clark & Lunn Investment Management Ltd. now owns 929,644 shares of the biopharmaceutical company’s stock worth $4,267,000 after acquiring an additional 110,262 shares during the last quarter. Finally, Marshall Wace LLP raised its stake in shares of Vanda Pharmaceuticals by 945.9% in the second quarter. Marshall Wace LLP now owns 471,720 shares of the biopharmaceutical company’s stock worth $2,227,000 after acquiring an additional 426,620 shares during the last quarter. 88.14% of the stock is owned by institutional investors.

About Vanda Pharmaceuticals

Vanda Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company’s marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia.